Document is current

Article History

Received: 17 February 2026

Accepted: 10 May 2026

First Online: 4 June 2026

Declarations

:

: JSA was partially supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health (T32AR007080-44S1) as well as by the National Institute of Dental and Craniofacial Research under 5T90DE034663-02.

: KFB has received grant funding from Tryp Therapeutics for a clinical trial of psilocybin-assisted therapy and sat on a data safety and monitoring board for an ongoing clinical trial with Vireo Health (unpaid). He has received grant funding from the National Institute on Drug Abuse, National Center for Complementary and Integrative Health, and the National Institutes of Arthritis, Musculoskeletal, and Skin Diseases of the National Institutes of Health. He has also received granting funding from the State of Michigan Veteran Marijuana Research Program. KFB has received speaking fees for lectures from the Southern Pain Society and the Michigan Center of Clinical Systems Improvement. He received an honorarium for developing a podcast on fibromyalgia with Viatris Inc. JSA was partially supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health (T32AR007080-44S1). JSA declares no other conflicts of interest. NP declares no conflicts of interest. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

: Not applicable.

: Not applicable.

: All authors contributed to the conceptualization of this article. KFB led the initial drafting of the article with support from NP and JSA. All authors provided critical revisions. All authors read and approved the final version of this article.

: Data sharing not applicable to this article as no datasets were generated or analysed during the current study.

: Not applicable.